VFY — Vitrafy Life Sciences Cashflow Statement
0.000.00%
- AU$77.90m
- AU$78.29m
- AU$0.07m
Annual cashflow statement for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.457 | 0.628 | 1.83 | 2.05 | 5.2 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.72 | -5.87 | -4.96 | -6.79 | -8.8 |
Capital Expenditures | -0.099 | -0.486 | -0.09 | -0.013 | -0.002 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | — | -10.1 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Cash from Investing Activities | -0.099 | -0.486 | -0.09 | -0.013 | -10.1 |
Financing Cash Flow Items | -0.454 | 0 | -0.103 | -0.639 | -3.25 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 8.91 | -0.058 | 5.8 | 11.5 | 32 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.09 | -6.42 | 0.758 | 4.69 | 13.1 |